Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06126952
Status:
COMPLETED
Last Update Posted:
2024-03-20
First Post:
2023-10-27
Brief Title:
Azelastine Allergen Chamber - Onset of Action Study
Sponsor:
MEDA Pharma GmbH Co KG
Organization:
Viatris Inc
Study Overview
Official Title:
Randomized Double-blind Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 015 Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone FuroateOlopatadine Hydrochloride Nasal Spray
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 015 in treating the nasal symptoms of seasonal allergic rhinitis SAR induced by an allergen challenge in an Environmental Exposure Unit EEU followed by a single dose and a 3-day treatment at home
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C2D03217 | OTHER | Cliantha Research Canada | None |